A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
← catalyst calendarNCT06246110 · readout ≤ 134 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
70estimated
Sites
38
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-06 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NSCLC
Interventions
- Drug: EIK1001
- Drug: Pembrolizumab
- Drug: Paclitaxel
- Drug: Pemetrexed
- Drug: Carboplatin
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with safety event during treatment
measured Up to 2 years
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed